Compare MCBS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | CSTL |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.1M | 940.8M |
| IPO Year | 2019 | 2019 |
| Metric | MCBS | CSTL |
|---|---|---|
| Price | $28.58 | $27.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $31.00 | ★ $47.17 |
| AVG Volume (30 Days) | 60.2K | ★ 425.2K |
| Earning Date | 05-01-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 24.75 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $36.76 | N/A |
| Revenue Next Year | $4.83 | $13.71 |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $24.24 | $14.59 |
| 52 Week High | $31.00 | $44.28 |
| Indicator | MCBS | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 28.16 |
| Support Level | $26.90 | $21.77 |
| Resistance Level | $29.00 | $34.97 |
| Average True Range (ATR) | 0.68 | 1.73 |
| MACD | -0.17 | -0.26 |
| Stochastic Oscillator | 17.29 | 2.24 |
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.